2026-06-14T03:31:10Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/96122025-05-12T11:55:49Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2052col_20.500.12105_16962col_20.500.12105_19616

00925njm 22002777a 4500 dc Rincon, Esther author Cejalvo, Teresa author Kanojia, Deepak author Alfranca, Arantzazu author Rodriguez-Milla, Miguel A author Gil Hoyos, Raul Andrés author Han, Yu author Zhang, Lingjiao author Alemany, Ramón author Lesniak, Maciej S author Garcia-Castro, Javier author 2017-07-11 Oncolytic virotherapy represents a promising alternative for cancer treatment; however, viral delivery to the tumor represents a major challenge. Mesenchymal stem cells (MSCs) chemotax to tumors, and can serve as a viral delivery tool. Previously, we demonstrated antitumor therapeutic efficacy for mesenchymal stem cells (MSCs) infected with the oncolytic human adenovirus ICOVIR5 (Celyvir) for treatment of neuroblastoma patients. Given the lack of suitable immunocompetent preclinical models, the mechanism underlying Celyvir antitumor activity remains unknown. In this study, we used the syngeneic murine CMT64 cell line as a human adenovirus-semi-permissive tumor model and demonstrate the homing capacity of mouse Celyvir (mCelyvir) to CMT64 tumors. We found that the combined treatment of mCelyvir and intratumoral injections (i.t.) of ICOVIR5 was more effective than treatment with i.t. ICOVIR5 alone. Interestingly, the superior therapeutic effect of the combined therapy was associated with a higher tumor infiltration of CD8+ and CD4+ T cells. Our findings suggest that the use of MSCs as carriers of oncolytic adenovirus can improve the clinical efficacy of anti-cancer virotherapy, not only by driving the adenovirus to tumors, but also through their potential to recruit T cells. Oncotarget. 2017 Jul 11;8(28):45415-45431. 10.18632/oncotarget.17557 1949-2553 1949-2553 Oncotarget 28525366 http://hdl.handle.net/20.500.12105/9612 Cancer Carriers Immunotherapy Mesenchymal stem cells Oncolytic adenoviruses Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model